This case report demonstrates that religious OCD responds comparably to standard OCD subtypes with optimized SSRI monotherapy or augmentation, challenging the notion of inherently poorer treatment outcomes.
A 12-month naturalistic study found that while both men and women with schizophrenia showed significant improvements on cariprazine, distinct gender-specific response profiles emerged across symptom domains.
A large-scale genomic study identified 641 novel risk genes for schizophrenia through network mapping, potentially informing future precision medicine approaches.
MapLight Therapeutics' Phase 2 trial for its autism drug ML-004 failed to meet its primary endpoint, prompting discussions with the FDA regarding the drug's future development.
Definium Therapeutics reported positive Phase 3 results for its LSD candidate demonstrating strong antidepressant effects, marking a significant clinical trial readout for psychedelic psychiatry.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Jun 16 – Jun 23)
- Consider that early single-dose benzodiazepine prescriptions following mass trauma do not appear to increase subsequent PTSD risk, challenging the traditional blanket avoidance of these agents in acute stress settings.
- Initiating psychotherapy is associated with significant simplification of psychotropic regimens, including reduced polypharmacy and benzodiazepine use, without increasing total medication dose.
- Religious OCD responds comparably to standard OCD subtypes with optimized SSRI monotherapy or augmentation, so do not assume inherently poorer outcomes based on the religious content of obsessions.
- In adults with dementia, nearly 8% initiate CNS-active polypharmacy primarily involving antidepressants and quetiapine, warranting careful review of prescribing guidelines to mitigate risks.
- ADHD medication use is associated with reduced risks of suicidality, criminality, drug misuse, and car accidents, supporting its broader protective benefits beyond symptom control.
- Cariprazine produces significant improvements in schizophrenia symptoms for both genders, but distinct gender-specific response profiles across symptom domains should guide individualized treatment adjustments.
- Definium Therapeutics' Phase 3 results for the LSD-based candidate DT120 show significant improvement in major depressive disorder, signaling potential advancement of psychedelic therapeutics in clinical practice.
- A large-scale genomic study identified 641 novel risk genes for schizophrenia through network mapping, which may inform future precision medicine approaches and target identification.
Journal Article 2
A large population-wide cohort study addresses the long-standing clinical question of whether post-trauma benzodiazepine prescribing increases subsequent PTSD risk, leveraging a natural experiment to mitigate confounding by indication.
A study indicates that ADHD medication use is associated with reduced risks of suicidality, criminality, drug misuse, and car accidents.
Drug Development 3
Definium Therapeutics reported positive Phase 3 results for its LSD-based candidate DT120 in major depressive disorder, indicating significant improvement in depression symptoms.
Definium Therapeutics reported positive Phase 3 results for DT120, an LSD-based therapy for major depression, showing significant symptom reduction compared to placebo.
Definium Therapeutics reports top-line Phase 3 data for its proprietary LSD formulation in a pivotal depression trial, signaling potential advancement of psychedelic therapeutics for major depressive disorder.
Diagnosis & Treatment 4
A large cohort study suggests that single early prescriptions of benzodiazepines after mass trauma do not increase PTSD risk, challenging the blanket guideline against their use for acute distress prevention.
A clinical trial is recruiting to evaluate temporal interference stimulation targeting the dACC for treating negative and cognitive symptoms in schizophrenia.
A large Medicare cohort study reveals that 7.8% of adults with dementia initiate CNS-active polypharmacy, primarily involving antidepressants and quetiapine, highlighting a need for prescribing guidelines to mitigate risks.
A large real-world cohort study demonstrates that initiating psychotherapy is associated with significant simplification of psychotropic regimens (reduced polypharmacy and benzodiazepine use) without increasing total medication dose.